BHVN

Biohaven Ltd.'s stock price has been influenced by several events over the past six months. On October 8, 2026, Biohaven entered a strategic licensing agreement with Ono Pharma for extracellular IgG degraders in Japan and select Asian regions, which resulted in a +0.34% change in stock price. On the same day, the FDA placed a partial clinical hold on new enrollment for Biohaven's BHV-7000 epilepsy drug program. On September 28, 2026, clinical data on BHV-1530 was selected for oral presentation at a symposium. On September 17, 2026, Biohaven disclosed options tied to an SVP's son in a Form 4 filing. On August 26, 2026, the company entered a strategic global licensing agreement with SK Biopharmaceuticals for its Kv7 Ion Channel Platform and Opakalim (BHV-7000) for epilepsy, leading to an +18.01% increase in stock price. On August 10, 2026, Biohaven reported its second-quarter 2026 financial results with a net loss of $137.3 million, or $0.91 per share, which saw the stock price decline by -0.34%. On July 27, 2026, a federal jury awarded Biohaven and Yale University $4 million in a trade secret misappropriation lawsuit, resulting in a +1.33% increase in stock price. Over the past six months, BHVN's stock has seen a 28.65% increase, although it experienced a -26.12% decrease over the last three months, a -17.37% fall in the last month, and a -9.92% fall in the last week. The largest daily move recorded between October 9, 2025, and October 9, 2026, was a -40.2% close on November 5, 2025.